970 results on '"Kuwana, M"'
Search Results
2. AB1645-PARE DISEASE FLARES IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING COVID-19 BREAKTHROUGH INFECTION: RESULT FROM COVAD E-SURVEY STUDY
- Author
-
Sieiro Santos, C., primary, Chen, J. P., additional, Nikiphorou, E., additional, Tseng, C. W., additional, Toro-Gutierrez, C. E., additional, Tan, A. L., additional, Nune, A., additional, Kadam, E., additional, Kuwana, M., additional, Day, J., additional, Saha, S., additional, Velikova, T., additional, Lilleker, J. B., additional, Vinicio Caballero, C., additional, Sen, P., additional, Chinoy, H., additional, Aggarwal, R., additional, Agarwal, V., additional, Gupta, L., additional, and Chen, Y. M., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
- Author
-
Allanore, Y., Khanna, D., Smith, V., Aringer, M., Hoffmann-Vold, A.M., Kuwana, M., Merkel, P.A., Stock, C., Vonk, M.C., Sambevski, S., Denton, C.P., Allanore, Y., Khanna, D., Smith, V., Aringer, M., Hoffmann-Vold, A.M., Kuwana, M., Merkel, P.A., Stock, C., Vonk, M.C., Sambevski, S., and Denton, C.P.
- Abstract
Contains fulltext : 305344.pdf (Publisher’s version ) (Open Access), OBJECTIVES: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomized to receive nintedanib or placebo. Patients who completed the SENSCIS trial were eligible to enter SENSCIS-ON, in which all patients received open-label nintedanib. RESULTS: Among 277 patients with lcSSc treated in the SENSCIS trial, the rate (s.e.) of decline in forced vital capacity (FVC; ml/year) over 52 weeks was -74.5 (19.2) in the placebo group and -49.1 (19.8) in the nintedanib group (difference: 25.3 [95% CI -28.9, 79.6]). Among 249 patients with data at week 52, mean (s.e.) change in FVC at week 52 was -86.4 (21.1) ml in the placebo group and -39.1 (22.2) ml in the nintedanib group. Among 183 patients with lcSSc who participated in SENSCIS-ON and had data at week 52, mean (s.e.) change in FVC from baseline to week 52 of SENSCIS-ON was -41.5 (24.0) ml in patients who took placebo in the SENSCIS trial and initiated nintedanib in SENSCIS-ON and -45.1 (19.1) ml in patients who took nintedanib in the SENSCIS trial and continued it in SENSCIS-ON. CONCLUSION: Patients with lcSSc may develop progressive fibrosing ILD. By targeting pulmonary fibrosis, nintedanib slows decline in lung function in patients with lcSSc and ILD. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT02597933 and NCT03313180.
- Published
- 2024
4. Defining anti-synthetase syndrome: a systematic literature review
- Author
-
Zanframundo, G, Faghihi-Kashani, S, Scire, C, Bonella, F, Corte, T, Doyle, T, Fiorentino, D, Gonzalez-Gay, M, Hudson, M, Kuwana, M, Lundberg, I, Mammen, A, Mchugh, N, Miller, F, Monteccucco, C, Oddis, C, Rojas-Serrano, J, Schmidt, J, Selva-O'Callaghan, A, Werth, V, Sakellariou, G, Aggarwal, R, Cavagna, L, Zanframundo G., Faghihi-Kashani S., Scire C. A., Bonella F., Corte T. J., Doyle T. J., Fiorentino D., Gonzalez-Gay M. A., Hudson M., Kuwana M., Lundberg I. E., Mammen A., McHugh N., Miller F. W., Monteccucco C., Oddis C. V., Rojas-Serrano J., Schmidt J., Selva-O'Callaghan A., Werth V. P., Sakellariou G., Aggarwal R., Cavagna L., Zanframundo, G, Faghihi-Kashani, S, Scire, C, Bonella, F, Corte, T, Doyle, T, Fiorentino, D, Gonzalez-Gay, M, Hudson, M, Kuwana, M, Lundberg, I, Mammen, A, Mchugh, N, Miller, F, Monteccucco, C, Oddis, C, Rojas-Serrano, J, Schmidt, J, Selva-O'Callaghan, A, Werth, V, Sakellariou, G, Aggarwal, R, Cavagna, L, Zanframundo G., Faghihi-Kashani S., Scire C. A., Bonella F., Corte T. J., Doyle T. J., Fiorentino D., Gonzalez-Gay M. A., Hudson M., Kuwana M., Lundberg I. E., Mammen A., McHugh N., Miller F. W., Monteccucco C., Oddis C. V., Rojas-Serrano J., Schmidt J., Selva-O'Callaghan A., Werth V. P., Sakellariou G., Aggarwal R., and Cavagna L.
- Abstract
Anti-synthetase syndrome (ASSD) is a heterogeneous autoimmune disease characterised by multi-system involvement with a wide variety of manifestations. Validated classification criteria are necessary to improve recognition and prevent misclassification, especially given the lack of reliable and standardised autoantibody testing. We systematically reviewed the literature to analyse proposed ASSD criteria, characteristics, and diagnostic performance. Methods We searched PubMed and Embase databases (01/01/1984 to 06/11/2018) and the ACR and EULAR meeting abstracts (2017-2018). Sensitivities, specificities, positive, negative likelihood ratios and risk of bias were calculated for ASSD criteria and key variables reported in the literature. We performed meta-analysis when appropriate. Results We retrieved 4,358 studies. We found 85 proposed ASSD criteria from a total of 82 studies. All but one study included anti-synthetase autoantibody (ARS) positivity in the ASSD criteria. Most studies required only one ASSD feature plus anti-ARS to define ASSD (n=64, 78%), whereas 16 studies required more than one ASSD variable plus anti-ARS. The only criteria not including anti-ARS positivity required 5 ASSD clinical features. We found limited data and wide variability in the diagnostic performance of each variable and definition proposed in the literature. Given these limitations we only meta-analysed the performance of individual muscle biopsy and clinical variables in diagnosing ASSD, which performed poorly. Conclusion The current ASSD criteria include a variety of serological, clinical, and histological features with wide variability amongst proposed definitions and the performance of these definitions has not been tested. This systematic literature review suggests the need for additional data and consensus-driven classification criteria for ASSD.
- Published
- 2022
5. AB0810 PERFORMANCE OF CIRCULATING BIOMARKERS FOR PREDICTING PROGRESSION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
- Author
-
Yomono, K., primary and Kuwana, M., additional
- Published
- 2023
- Full Text
- View/download PDF
6. POS0558 FLARES OF AUTOIMMUNE RHEUMATIC DISEASE FOLLOWING COVID-19 INFECTION: OBSERVATIONS FROM THE COVAD STUDY
- Author
-
Ravichandran, N., primary, Sandhu, N., additional, Nune, A., additional, Day, J., additional, Sen, P., additional, Nikiphorou, E., additional, Tan, A. L., additional, Joshi, M., additional, Saha, S., additional, Katsuyuki Shinjo, S., additional, Jagtap, K., additional, Agarwal, V., additional, Ziade, N., additional, Velikova, T., additional, Milchert, M., additional, Kuwana, M., additional, Makol, A., additional, Chinoy, H., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
7. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS
- Author
-
Bruni, C., primary, Tofani, L., additional, Fretheim, H., additional, Weber, Y., additional, Hachulla, E., additional, Carreira, P., additional, Giuggioli, D., additional, Airò, P., additional, Siegert, E., additional, Müller-Ladner, U., additional, Matucci-Cerinic, M., additional, Riemekasten, G., additional, Simeon Aznar, C. P., additional, De Vries-Bouwstra, J., additional, Saketkoo, L. A., additional, Distler, J., additional, Balbir-Gurman, A., additional, Castellví, I., additional, Zanatta, E., additional, Smith, V., additional, Denton, C. P., additional, Maurer, B., additional, Giollo, A., additional, Iannone, F., additional, Dagna, L., additional, Truchetet, M. E., additional, Kuwana, M., additional, Allanore, Y., additional, Tanaka, Y., additional, Martin, M., additional, Rosato, E., additional, Gheorghiu, A. M., additional, Del Galdo, F., additional, Solanki, K., additional, Vacca, A., additional, Resende, C., additional, Vieira, S., additional, Czirják, L., additional, Baresic, M., additional, Cantatore, F. P., additional, Riccieri, V., additional, Andréasson, K., additional, Chung, L., additional, Souza Muller, C., additional, Opris-Belinski, D., additional, Rednic, S., additional, Sfikakis, P., additional, Levy, Y., additional, Hsu, V., additional, Heitmann, S., additional, Henes, J., additional, Moroncini, G., additional, Iudici, M., additional, De Langhe, E., additional, Herrick, A., additional, Montecucco, C., additional, Hoffmann-Vold, A. M., additional, and Distler, O., additional
- Published
- 2023
- Full Text
- View/download PDF
8. POS1216 MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY)
- Author
-
Fornaro, M., primary, Venerito, V., additional, Iannone, F., additional, Ravichandran, N., additional, Nikiphorou, E., additional, Joshi, M., additional, Tan, A. L., additional, Saha, S., additional, Katsuyuki Shinjo, S., additional, Agarwal, V., additional, Ziade, N., additional, Velikova, T., additional, Jagtap, K., additional, Milchert, M., additional, Parodis, I., additional, Gracia-Ramos, A. E., additional, Cavagna, L., additional, Kuwana, M., additional, Knitza, J., additional, Makol, A., additional, Dzifa, D., additional, Toro Gutierrez, C. E., additional, Vinicio Caballero, C., additional, Distler, O., additional, Day, J., additional, Study, C., additional, Chinoy, H., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
9. AB1295 SAFETY AND TOLERANCE OF ANTI-SARS-CoV-2 VACCINES IN SJÖGREN’S SYNDROME: RESULTS FROM THE COVAD STUDY
- Author
-
Alunno, A., primary, Carubbi, F., additional, Gracia-Ramos, A. E., additional, Ziade, N., additional, Agarwal, V., additional, Velikova, T., additional, Kuwana, M., additional, Makol, A., additional, Chatterjee, T., additional, Joshi, M., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
10. POS0573 COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY
- Author
-
Gupta, L., primary, Ravichandran, N., additional, Venerito, V., additional, Dey, M., additional, Sen, P., additional, Saha, S., additional, Tan, A. L., additional, Katsuyuki Shinjo, S., additional, Agarwal, V., additional, Joshi, M., additional, Ziade, N., additional, Velikova, T., additional, Jagtap, K., additional, Milchert, M., additional, Parodis, I., additional, Gracia-Ramos, A. E., additional, Cavagna, L., additional, Kuwana, M., additional, Knitza, J., additional, Makol, A., additional, Dzifa, D., additional, Toro Gutierrez, C. E., additional, Vinicio Caballero, C., additional, Distler, O., additional, Day, J., additional, Chinoy, H., additional, Aggarwal, R., additional, and Nikiphorou, E., additional
- Published
- 2023
- Full Text
- View/download PDF
11. POS0273 POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVAD STUDY
- Author
-
Sen, P., primary, Ravichandran, N., additional, Joshi, M., additional, Saha, S., additional, Jagtap, K., additional, Agarwal, V., additional, Distler, O., additional, Nikiphorou, E., additional, Tan, A. L., additional, Katsuyuki Shinjo, S., additional, Ziade, N., additional, Velikova, T., additional, Milchert, M., additional, Parodis, I., additional, Gracia-Ramos, A. E., additional, Cavagna, L., additional, Kuwana, M., additional, Knitza, J., additional, Makol, A., additional, Patel, A., additional, Pauling, J., additional, Wincup, C., additional, Barman, B., additional, Zamora-Tehozol, E. A., additional, Rojas-Serrano, J., additional, Garcia-De La Torre, I., additional, Colunga-Pedraza, I. J., additional, Merayo-Chalico, J., additional, Katchamart, W., additional, Goo, P. A., additional, Chen, Y. M., additional, Hoff, L. S., additional, Kibbi, L., additional, Halabi, H., additional, Vaidya, B., additional, Shaharir, S. S., additional, Shumnalieva, R., additional, Hasan, A. T. M. T., additional, Dzifa, D., additional, Toro Gutierrez, C. E., additional, Vinicio Caballero, C., additional, Lilleker, J. B., additional, Salim, B., additional, Gheita, T. A., additional, Chatterjee, T., additional, Nune, A., additional, Saavedra, M. A., additional, Day, J., additional, Chinoy, H., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
12. POS1254 REDUCED HEALTH-RELATED QUALITY OF LIFE USING PROMIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL ANALYSIS FROM THE INTERNATIONAL COVAD-2 E-SURVEY
- Author
-
Yomono, K., primary, Li, Y., additional, Maroufy, V., additional, Ravichandran, N., additional, Yoshida, A., additional, Jagtap, K., additional, Velikova, T., additional, Sen, P., additional, Cavagna, L., additional, Agarwal, V., additional, Knitza, J., additional, Makol, A., additional, Dzifa, D., additional, Toro Gutierrez, C. E., additional, Chatterjee, T., additional, Patel, A., additional, Aggarwal, R., additional, Gupta, L., additional, and Kuwana, M., additional
- Published
- 2023
- Full Text
- View/download PDF
13. POS0971 A COMPARISON OF MYOSITIS AUTOANTIBODY AND CLINICAL CHARACTERISTICS AMONG RACIAL GROUPS IN ASIA AND AUSTRALASIA – A COLLABORATIVE MULTICENTRE EFFORT BY THE APLAR MYOSITIS SIG
- Author
-
He, J., primary, Low, A., additional, Kuwana, M., additional, Gupta, L., additional, Raja, J., additional, Fong, W., additional, Wangkaew, S., additional, So, H., additional, Gono, T., additional, and Limaye, V., additional
- Published
- 2023
- Full Text
- View/download PDF
14. POS1231 IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A CROSS-SECTIONAL ANALYSIS FROM AN INTERNATIONAL E-SURVEY
- Author
-
Yoshida, A., primary, LI, Y., additional, Maroufy, V., additional, Kuwana, M., additional, Ravichandran, N., additional, Makol, A., additional, Sen, P., additional, Lilleker, J. B., additional, Agarwal, V., additional, Kardes, S., additional, Day, J., additional, Milchert, M., additional, Joshi, M., additional, Gheita, T. A., additional, Salim, B., additional, Velikova, T., additional, Gracia-Ramos, A. E., additional, Parodis, I., additional, Nikiphorou, E., additional, Tan, A. L., additional, Nune, A., additional, Cavagna, L., additional, Saavedra, M. A., additional, Katsuyuki Shinjo, S., additional, Ziade, N., additional, Knitza, J., additional, Distler, O., additional, Chinoy, H., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
15. OP0128 PHARMACOKINETICS AND PHARMACODYNAMICS OF METHOTREXATE POLYGLUTAMATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH LOW OR HIGH DOSE-METHOTREXATE IN COMBINATION WITH ADALIMUMAB: RESULTS FROM THE MIRACLE TRIAL
- Author
-
Tamai, H., primary, Ikeda, K., additional, Miyamoto, T., additional, Taguchi, H., additional, Kuo, C. F., additional, Shin, K., additional, Hirata, S., additional, Okano, Y., additional, Sato, S., additional, Yasuoka, H., additional, Choi, I. A., additional, Park, S. H., additional, Weng, M. Y., additional, Kuwana, M., additional, Lee, Y. J., additional, Ishii, T., additional, Kim, J., additional, Kameda, H., additional, Kojima, T., additional, Baek, H. J., additional, Hsu, P. N., additional, Huang, C. M., additional, Cheng, T. T., additional, Sung, W. Y., additional, Tsai, W. C., additional, Taninaga, T., additional, Mori, M., additional, Miyagishi, H., additional, Sato, Y., additional, Takeuchi, T., additional, and Kaneko, Y., additional
- Published
- 2023
- Full Text
- View/download PDF
16. POS0880 COMPARATIVE DISEASE BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: DATA FROM COVAD PATIENT-REPORTED E-SURVEY
- Author
-
Venerito, V., primary, Fornaro, M., additional, Iannone, F., additional, Cavagna, L., additional, Kuwana, M., additional, Agarwal, V., additional, Ravichandran, N., additional, Day, J., additional, Joshi, M., additional, Saha, S., additional, Shaharir, S. S., additional, Katchamart, W., additional, Goo, P. A., additional, Traboco, L., additional, Chen, Y. M., additional, Sen, P., additional, Lilleker, J. B., additional, Nune, A., additional, Pauling, J., additional, Wincup, C., additional, Tan, A. L., additional, Ziade, N., additional, Milchert, M., additional, Gracia-Ramos, A. E., additional, Vinicio Caballero, C., additional, Study, C., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
17. OP0082 COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY
- Author
-
Andreoli, L., primary, Lini, D., additional, Schreiber, K., additional, Sen, P., additional, Ravichandran, N., additional, Parodis, I., additional, Toro Gutierrez, C. E., additional, Katchamart, W., additional, Goo, P. A., additional, Shumnalieva, R., additional, Chibuzo, O. C., additional, Velikova, T., additional, Day, J., additional, Joshi, M., additional, Katsuyuki Shinjo, S., additional, Gracia-Ramos, A. E., additional, Cavagna, L., additional, Kuwana, M., additional, Knitza, J., additional, Makol, A., additional, Chen, Y. M., additional, Study, C., additional, Chinoy, H., additional, Agarwal, V., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
18. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial*
- Author
-
Gläser, S, additional, Khanna, D, additional, Maher, T, additional, Volkmann, E, additional, Allanore, Y, additional, Smith, V, additional, Assassi, S, additional, Kreuter, M, additional, Hoffmann-Vold, A, additional, Kuwana, M, additional, Stock, C, additional, Alves, M, additional, Sambevski, S, additional, and Denton, C, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Effect of nintedanib on circulating biomarkers in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)*
- Author
-
Prasse, A, additional, Assassi, S, additional, Kuwana, M, additional, Denton, C, additional, Maher, T, additional, Diefenbach, C, additional, Ittrich, C, additional, Gahlemann, M, additional, and Distler, O, additional
- Published
- 2023
- Full Text
- View/download PDF
20. COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES : RESULTS FROM THE COVAD STUDY
- Author
-
Andreoli, L., Lini, D., Schreiber, K., Sen, P., Ravichandran, N., Parodis, Ioannis, Toro Gutierrez, C. E., Katchamart, W., Goo, P. A., Shumnalieva, R., Chibuzo, O. C., Velikova, T., Day, J., Joshi, M., Katsuyuki Shinjo, S., Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Chen, Y. M., Chinoy, H., Agarwal, V., Aggarwal, R., Gupta, L., Andreoli, L., Lini, D., Schreiber, K., Sen, P., Ravichandran, N., Parodis, Ioannis, Toro Gutierrez, C. E., Katchamart, W., Goo, P. A., Shumnalieva, R., Chibuzo, O. C., Velikova, T., Day, J., Joshi, M., Katsuyuki Shinjo, S., Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Chen, Y. M., Chinoy, H., Agarwal, V., Aggarwal, R., and Gupta, L.
- Abstract
Background: COVID-19 vaccine hesitancy among pregnant and breastfeeding women with autoimmune diseases (AID) is often attributed to the fear of adverse events (AE) and disease flares (DF). No data are available regarding COVID-19 vaccine safety in this population. Objectives: We aimed at describing delayed-onset (>7 days) vaccine-related AE (minor and major), DF, and related AID treatment modifications from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods: Among complete responses from 9201 participants as of June 21, 2022, 6787 (73.8%) were women. Six subgroups were identified upon diagnosis of AID vs healthy controls (HC) and their pregnancy/breastfeeding status at the time of any dose of vaccine (Figure 1). Results: Forty pregnant and 52 breastfeeding AID patients were identified and their vaccination rates (at least one dose) was 100% and 96.2%, respectively (Table 1). Overall AE, minor AE, and major AE were reported significantly more frequently by pregnant than non-pregnant patients (45% vs. 26%, p=0.01; 40% vs. 25.9%, p=0.03; 17.5% vs. 4.6%, p<0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC. Post-vaccination DF were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18% of age- and disease-matched control patients (n=2315). All DF in pregnant/breastfeeding patients were managed with glucocorticoids and a fifth of them required initiation or change in immunosuppressive treatment. Conclusion: This study provides the first insights into the safety of COVID-19 vaccination during the antenatal period in women with AID. While AEs were more commonly reported by pregnant patients with AID, these were no higher than among pregnant healthy controls without AID. These observations are reassuring, likely to strengthen physician-patient communication and overcome hesitancy as the benefits for the mother and fetus by passive immunization are
- Published
- 2023
- Full Text
- View/download PDF
21. IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES : A CROSS-SECTIONAL ANALYSIS FROM AN INTERNATIONAL SURVEY
- Author
-
Yoshida, A., Li, Y., Maroufy, V., Kuwana, M., Ravichandran, N., Makol, A., Sen, P., Lilleker, J. B., Agarwal, V., Kardes, S., Day, J., Milchert, M., Joshi, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Nikiphorou, E., Tan, A. L., Nune, A., Cavagna, L., Saavedra, M. A., Katsuyuki Shinjo, S., Ziade, N., Knitza, J., Distler, O., Chinoy, H., Aggarwal, R., Gupta, L., Yoshida, A., Li, Y., Maroufy, V., Kuwana, M., Ravichandran, N., Makol, A., Sen, P., Lilleker, J. B., Agarwal, V., Kardes, S., Day, J., Milchert, M., Joshi, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Nikiphorou, E., Tan, A. L., Nune, A., Cavagna, L., Saavedra, M. A., Katsuyuki Shinjo, S., Ziade, N., Knitza, J., Distler, O., Chinoy, H., Aggarwal, R., and Gupta, L.
- Abstract
Background: Comprehensive and large-scale assessment of health-related quality of life in patients with idiopathic inflammatory myopathies (IIMs) worldwide is lacking. The second COVID-19 vaccination in autoimmune disease (COVAD-2) study [1] is an international, multicentre, self-reported e-survey assessing several aspects of COVID-19 infection and vaccination as well as validated patient-reported outcome measures (PROMs) to outline patient experience in various autoimmune diseases (AIDs), with a particular focus on IIMs. Objectives: To investigate physical and mental health in a global cohort of IIM patients compared to those with non-IIM autoimmune inflammatory rheumatic diseases (AIRDs), non-rheumatic AIDs (NRAIDs), and those without AIDs (controls), using Patient-Reported Outcome Measurement Information System (PROMIS) global health data obtained from the COVAD-2 survey. Methods: Demographics, AID diagnoses, comorbidities, disease activity, treatments, and PROMs were extracted from the COVAD-2 database. The primary outcomes were PROMIS Global Physical Health (GPH) and Global Mental Health (GMH) scores. Secondary outcomes included PROMIS physical function short form-10a (PROMIS PF-10a), pain visual analogue scale (VAS), and PROMIS Fatigue-4a scores. Each outcome was compared between IIMs, non-IIM AIRDs, NRAIDs, and controls. Factors affecting GPH and GMH scores in IIMs were identified using multivariable regression analysis. Results: A total of 10,502 complete responses from 1582 IIMs, 4700 non-IIM AIRDs, 545 NRAIDs, and 3675 controls, which accrued as of May 2022, were analysed. Patients with IIMs were older [59±14 (IIMs) vs. 48±14 (non-IIM AIRDs) vs. 45±14 (NRAIDs) vs. 40±14 (controls) years, p<0.001] and more likely to be Caucasian [82.7% (IIMs) vs. 53.2% (non-IIM AIRDs) vs. 62.4% (NRAIDs) vs. 34.5% (controls), p<0.001]. Among IIMs, dermatomyositis (DM) and juvenile DM were the most common (31.4%), followed by inclusion body myositis (IBM) (24.9%). Patie
- Published
- 2023
- Full Text
- View/download PDF
22. COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES : DATA FROM THE COVAD STUDY
- Author
-
Gupta, L., Ravichandran, N., Venerito, V., Dey, M., Sen, P., Saha, S., Tan, A. L., Shinjo, S. Katsuyuki, Agarwal, V., Joshi, M., Ziade, N., Velikova, T., Jagtap, K., Milchert, M., Parodis, Ioannis, Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Dzifa, D., Gutierrez, C. E. Toro, Caballero, C. Vinicio, Distler, O., Day, J., Chinoy, H., Aggarwal, R., Nikiphorou, E., Gupta, L., Ravichandran, N., Venerito, V., Dey, M., Sen, P., Saha, S., Tan, A. L., Shinjo, S. Katsuyuki, Agarwal, V., Joshi, M., Ziade, N., Velikova, T., Jagtap, K., Milchert, M., Parodis, Ioannis, Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Dzifa, D., Gutierrez, C. E. Toro, Caballero, C. Vinicio, Distler, O., Day, J., Chinoy, H., Aggarwal, R., and Nikiphorou, E.
- Abstract
Background: Comorbidities have a profound impact on the QoL of patients living with autoimmune rheumatic diseases (AIRDs). Unfortunately, global data on the burden of comorbidities and its impact on health outcomes in this vulnerable group is scarce. Objectives: We studied the prevalence, distribution and clustering of comorbidities and multimorbidity among patients with AIRDs and healthy controls (HCs) and its impact on health outcomes, utilizing data from the ongoing 2nd COVAD study. Methods: The COVAD study is a global e-survey that embodies patient voice while empowering collaborators and young researchers. The study group of 157 physicians across 106 countries from February-June 2022 captured details of AIRDs, autoimmune and non-autoimmune comorbidities, and validated patient reported outcomes. Human Development Index (UNDP 2021-22) of country of residence was taken as a surrogate marker for socioeconomic status (SES). Basic multimorbidity (BM), Complex multimorbidity (CM), Autoimmune multimorbidity (AM) are defined as the co-occurrence of ≥2 non-rheumatic comorbidities, ≥3 non-rheumatic chronic conditions affecting ≥3 different organ systems [1] and ≥3 autoimmune diseases (AIDs) in an individual respectively. PROMIS global physical health (PGP), mental health (PGM), fatigue 4a (F4a) and physical function short form (SF10) scores were calculated for the different groups and compared using descriptive statistics, linear regression and cluster analysis (hierarchical followed by K means). Results: Of 17,612 total respondents, 6149 (62.7%) had underlying AIRDs and 3652 (37.3%) were HCs, with female (80.8%) and Caucasian (53.9%) predominance in the former. All types of multimorbidity were more frequent in AIRDs than HCs, including any comorbidity (77.1% versus 25.0%; OR: 2.9; 2.7-3.2), BM (21.0% vs 6.2%; 4.0; 3.4-4.6), and CM (3.1% vs 0.5%; 6.4; 3.9-10.4), and with prevalence increasing with age (p<0.001) (Figure 1A, B). Comorbidity prevalence was the highest amo
- Published
- 2023
- Full Text
- View/download PDF
23. MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES : DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY)
- Author
-
Fornaro, M., Venerito, V., Iannone, F., Ravichandran, N., Nikiphorou, E., Joshi, M., Tan, A. L., Saha, S., Shinjo, S. Katsuyuki, Agarwal, V., Ziade, N., Velikova, T., Jagtap, K., Milchert, M., Parodis, Ioannis, Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Dzifa, D., Toro Gutierrez, C. E., Vinicio Caballero, C., Distler, O., Day, J., Chinoy, H., Aggarwal, R., Gupta, L., Fornaro, M., Venerito, V., Iannone, F., Ravichandran, N., Nikiphorou, E., Joshi, M., Tan, A. L., Saha, S., Shinjo, S. Katsuyuki, Agarwal, V., Ziade, N., Velikova, T., Jagtap, K., Milchert, M., Parodis, Ioannis, Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Dzifa, D., Toro Gutierrez, C. E., Vinicio Caballero, C., Distler, O., Day, J., Chinoy, H., Aggarwal, R., and Gupta, L.
- Abstract
Background: Prevalence of comorbidities and their impact on health outcomes in Idiopathic inflammatory myopathies (IIMs) is limited. Objectives: This study aimed to explore the prevalence of multimorbidity in patients with IIMs, other autoimmune rheumatic diseases (AIRDs) and Healthy controls (HCs). We further explore the impact of comorbidities on patients’ physical, mental, and social health assessed by the Patient-Reported Outcome Measurement Information System (PROMIS instruments). Methods: Data for this study were acquired from the COVAD 2 e-survey hosted by a study group consisting of 167 collaborators in 110 countries. Basic multimorbidity (BM) was defined as the co-occurrence of two or more comorbidities in an individual, while complex multimorbidity (CM) signified the co-occurrence of 3 or more chronic conditions affecting 3 or more different organ systems. PROMIS global physical health (PGP), mental health (PGM), fatigue 4a (F4a) and physical function short form (SF10) were analysed using descriptive statistics and linear regression models. Hierarchical Clustering on Principal Components was performed to outline the grouping. Results: Of 10740 complete respondents, 1558 IIMs, 4591 AIRDs and 3652 HCs were analysed. Individuals with IIMs exhibited high burden of any comorbidity (OR: 1.62 vs AIRDs and 2.95 vs HCs,p<0.01), BM (OR 1.66 vs AIRDs and 3.52 vs HCs,p<0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs,p<0.01), and mental health disorders (MHDs) (OR 1.33 vs AIRDs and 2.63 vs HCs,p<0.01). IIM patients with comorbidities (and MHDs) had worse physical function (low PGP, PGM, SF10 and higher F4a scores, all p<0.001). Worse physical function (PGP) was predicted by age (0.35; 0.030), active disease (-1.51; <0.001), BM (-1.11; <0.001), and MHDs (-1.47; <0.001). PGM was impacted by age (0.51; 0.004), active disease (-1.34, <0.001), BM (-0.75; 0.001) and MHDs (-2.22; <0.001). Determinants of SF10a were age (-3.86; <0.001), active dis
- Published
- 2023
- Full Text
- View/download PDF
24. Poursuite du traitement par le nintédanib chez les patients atteints de sclérodermie systémique cutanée limitée (SCSCL) et de pneumopathie interstitielle diffuse (PID)
- Author
-
Allanore, Y., primary, Khanna, D., additional, Smith, V., additional, Aringer, M., additional, Hoffmann-Vold, A.M., additional, Kuwana, M., additional, Merkel, P.A., additional, James, A., additional, Sambeski, S., additional, Alves, M., additional, and Denton, C.P., additional
- Published
- 2022
- Full Text
- View/download PDF
25. Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
- Author
-
Sen, P, Naveen, R, Houshmand, N, Kia, Sm, Joshi, M, Saha, S, Jagtap, K, Agarwal, V, Nune, A, Nikiphorou, E, Tan, Al, Shinjo, Sk, Ziade, N, Velikova, T, Milchert, M, Parodis, I, Gracia-Ramos, Ae, Cavagna, L, Kuwana, M, Knitza, J, Makol, A, Patel, A, Pauling, Jd, Wincup, C, Barman, B, Tehozol, Eaz, Serrano, Jr, de la Torre, I, Colunga-Pedraza, Ij, Merayo-Chalico, J, Chibuzo, Oc, Katchamart, W, Goo, Pa, Shumnalieva, R, Chen, Ym, Hoff, Ls, El Kibbi, L, Halabi, H, Vaidya, B, Shaharir, Ss, Hasan, Atmt, Dey, D, Gutierrez, Cet, Caballero-Uribe, Cv, Lilleker, Jb, Salim, B, Gheita, T, Chatterjee, T, Distler, O, Saavedra, Ma, Day, J, Chinoy, H, COVAD Study Grp, Kardes, S, Kardes, Sa, Andreoli, L, Lini, D, Screiber, K, Vince, Mn, Singh, Yp, Ranjan, R, Jain, A, Pandya, Sc, Pilania, Rk, Sharma, A, Manoj, Mm, Gupta, V, Kavadichanda, Cg, Patro, Ps, Ajmani, S, Phatak, S, Goswami, Rp, Chowdhury, Ac, Mathew, Aj, Shenoy, P, Asranna, A, Bommakanti, Kt, Shukla, A, Pande, Ar, Chandwar, K, Ghodke, A, Boro, H, Fazal, Zz, Cansu, Du, Yildirim, R, Gasparyan, Ay, Del Papa, N, Sambataro, G, Fabiola, A, Govoni, M, Parisi, S, Bocci, Eb, Sebastiani, Gd, Fusaro, E, Sebastiani, M, Quartuccio, L, Franceschini, F, Sainaghi, Pp, Orsolini, G, De Angelis, R, Danielli, Mg, Venerito, V, Grignaschi, S, Giollo, A, Alluno, A, Ioannone, F, Fornaro, M, Traboco, Ls, Wibowo, Sak, Loarce-Martos, J, Prieto-Gonzalez, S, Gonzalez, Ra, Yoshida, A, Nakashima, R, Sato, S, Kimura, N, Kaneko, Y, Gono, T, Tomaras, S, Proft, Fn, Holzer, Mt, Gromova, Ma, Aharonov, O, Griger, Z, Hmamouchi, I, El Bouchti, I, Baba, Z, Giannini, M, Maurier, F, Campagne, J, Meyer, A, Langguth, D, Limaye, V, Needham, M, Srivastav, N, Hudson, M, Landon-Cardinal, O, Zuleta, Wgr, Arbelaez, A, Cajas, J, Silva, Jap, Fonseca, Je, Zimba, O, Bohdana, D, Ima-Edomwonyi, U, Dedeke, I, Airenakho, E, Madu, Nh, Yerima, A, Olaosebikan, H, Becky, A, Koussougbo, Od, Palalane, E, So, H, Ugarte-Gil, Mf, Chinchay, L, Bernaola, Jp, Pimentel, V, Fathi, Hm, Mohammed, Rha, Harifi, G, Fuentes-Silva, Y, Cabriza, K, Losanto, J, Colaman, N, Cachafeiro-Vilar, A, Bautista, Gg, Ejg, Ho, Gonzalez, R, Nunez, Ls, Vergara, Mc, Baez, Jt, Alonzo, H, Pastelin, Cbs, Salinas, Rg, Obiols, Aq, Chavez, N, Ordonez, Ab, Argueta, S, Llerena, Gar, Sierra-Zorita, R, Arrieta, D, Hidalgo, Er, Saenz, R, Escalante, Mi, Morales, R, Calapaqui, W, Quezada, I, Arredondo, G, Aggarwal, R, and Gupta, L
- Subjects
Rheumatology ,idiopathic inflammatory myopathies ,COVID-19 vaccines ,vaccine hesitancy ,registries ,Pharmacology (medical) ,autoimmune disease - Abstract
ObjectiveCOVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys.MethodsThe first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups.ResultsWe analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P ConclusionVaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
- Published
- 2023
26. Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey
- Author
-
Naveen, R., Thakare, D. R., Kuwana, M., Pauling, J. D., Day, J., Joshi, M., Parodis, I., Sen, P., Jagtap, K., Nikiphorou, E., Saha, S., Agarwal, V., Chatterjee, T., Lilleker, J. B., Kardes, S., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Tan, A. L., Nune, A., Cavagna, L., Saavedra, M. A., Shinjo, S. K., Ziade, N., Knitza, J., Distler, O., Chinoy, H., Barman, B., Singh, Y. P., Ranjan, R., Jain, A., Pandya, S. C., Pilania, R. K., Sharma, A., Manesh Manoj, M., Gupta, V., Kavadichanda, C. G., Patro, P. S., Ajmani, S., Phatak, S., Goswami, R. P., Chowdhury, A. C., Mathew, A. J., Shenoy, P., Asranna, A., Bommakanti, K. T., Shukla, A., Pande, A. R., Chandwar, K., Cansu, D. U., Wincup, C., Makol, A., Del Papa, N., Sambataro, G., Fabiola, A., Govoni, M., Parisi, S., Bocci, E. B., Sebastiani, G. D., Fusaro, E., Sebastiani, M., Quartuccio, L., Franceschini, F., Sainaghi, P. P., Orsolini, G., De Angelis, R., Danielli, M. G., Venerito, V., Traboco, L. S., Wibowo, S. A. K., Serrano, J. R., La Torre, I. G. -D., Tehozol, E. A. Z., Loarce-Martos, J., Prieto-Gonzalez, S., Gonzalez, R. A., Yoshida, A., Nakashima, R., Sato, S., Kimura, N., Kaneko, Y., Tomaras, S., Gromova, M. A., Aharonov, O., Hmamouchi, I., Hoff, L. S., Giannini, M., Maurier, F., Campagne, J., Meyer, A., Nagy-Vincze, M., Langguth, D., Limaye, V., Needham, M., Srivastav, N., Hudson, M., Landon-Cardinal, O., Shaharir, S. S., Zuleta, W. G. R., Silva, J. A. P., Fonseca, J. E., Zimba, O., Aggarwal, R., and Gupta, L.
- Subjects
Adverse events ,Autoimmune diseases ,Vaccination ,COVID-19 ,Systemic sclerosis - Published
- 2023
27. Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort
- Author
-
Michael Hughes 1 2, Suiyuan Huang 3 4, Juan Jose Alegre-Sancho 5, Patricia E Carreira 6, Merete Engelhart 7, Eric Hachulla 8, Joerg Henes 9, Eduardo Kerzberg 10, Maria Rosa Pozzi 11, Gabriela Riemekasten 12, Vanessa Smith 13, Gabriella Szücs 14, Marie Vanthuyne 15, Elisabetta Zanatta 16, Oliver Distler 17, Armando G Gabrielli 18, Anna-Maria Hoffmann-Vold 19, Virginia D Steen 20, Dinesh Khanna 3 21, EUSTAR Airò P, Allanore A, Ananieva Lp, Anic B, Balbir-Gurman A, Becvar R, Benvenuti F, Cantatore F P, Chung L S, Cuomo G, Cutolo M, Czirják L, Damjanov N, de Vries-Bouwstra J, Del Galdo F, Distler J, Eyerich K, Farge D, Foti R, Gheorghiu A M, Giollo A, Heitmann S, Herrick A, Hesselstrand R, Hsu I M, Hunzelmann N, Iannone F, Iudici M, Ionescuc M R, Ingegnoli F, Jose J, Joven B E, Kerzberg E, Kucharz E J, Kuwana M, Langhe E D, Launay D, Lefebvre P, Litinsky I, García de la Peña Lefebvre P, González-Martín J J, Li M, Loyo E, Martin T, Matucci-Cerinic M, Maurer B, Moroncini G, Mouthon L, Müller Cs, Müller-Ladner U, Novak S, Pastor P, Pecher A-C, Pellerito R, Pozzi M R, Oksel F, Rednic S, Rezus E, Riccieri V, Rosato E, Saketkoo L A, Salvador M J, Schmeiser T, Selmi C F, Sibilia J, Siegert E, Solanki K, Sommerlatte S, Spertini F, Stamenkovic B, Stamp L, Tanaseanu C-M, Tikly M, Tineo C, Ullman S, Üprus M, Vanthuyne M, Veale D, Walker U, Wiland P, Yargucu F, Yavuz S, University of Zurich, Michael Hughes, 1 2, Suiyuan Huang, 3 4, Juan Jose Alegre-Sancho, 5, Patricia, E Carreira 6, Merete Engelhart, 7, Eric Hachulla, 8, Joerg Henes, 9, Eduardo Kerzberg, 10, Maria Rosa Pozzi, 11, Gabriela Riemekasten, 12, Vanessa Smith, 13, Gabriella Szücs, 14, Marie Vanthuyne, 15, Elisabetta Zanatta, 16, Oliver Distler, 17, Armando, G Gabrielli 18, Anna-Maria Hoffmann-Vold, 19, Virginia, D Steen 20, Dinesh Khanna, 3 21, EUSTAR Airò, P, Allanore, A, Ananieva, Lp, Anic, B, Balbir-Gurman, A, Becvar, R, Benvenuti, F, Cantatore, F P, Chung, L S, Cuomo, G, Cutolo, M, Czirják, L, Damjanov, N, de Vries-Bouwstra, J, Del Galdo, F, Distler, J, Eyerich, K, Farge, D, Foti, R, Gheorghiu, A M, Giollo, A, Heitmann, S, Herrick, A, Hesselstrand, R, Hsu, I M, Hunzelmann, N, Iannone, F, Iudici, M, Ionescuc, M R, Ingegnoli, F, Jose, J, Joven, B E, Kerzberg, E, Kucharz, E J, Kuwana, M, Langhe, E D, Launay, D, Lefebvre, P, Litinsky, I, García de la Peña Lefebvre, P, González-Martín, J J, Li, M, Loyo, E, Martin, T, Matucci-Cerinic, M, Maurer, B, Moroncini, G, Mouthon, L, Müller, C, Müller-Ladner, U, Novak, S, Pastor, P, Pecher, A-C, Pellerito, R, Pozzi, M R, Oksel, F, Rednic, S, Rezus, E, Riccieri, V, Rosato, E, Saketkoo, L A, Salvador, M J, Schmeiser, T, Selmi, C F, Sibilia, J, Siegert, E, Solanki, K, Sommerlatte, S, Spertini, F, Stamenkovic, B, Stamp, L, Tanaseanu, C-M, Tikly, M, Tineo, C, Ullman, S, Üprus, M, Vanthuyne, M, Veale, D, Walker, U, Wiland, P, Yargucu, F, and Yavuz, S
- Subjects
Rheumatology ,Cohort enrichment ,10051 Rheumatology Clinic and Institute of Physical Medicine ,Late disease ,Systemic sclerosis ,Pharmacology (medical) ,610 Medicine & health ,Fibrosis ,Clinical trial design ,Scleroderma ,Skin - Abstract
Objectives The early trajectory of skin fibrosis provides insights into the disease course of systemic sclerosis (SSc) including mortality; however, little is known about late skin fibrosis. The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc. Methods We developed and tested three conceptual scenarios of late (>5 years after first non-RP feature) skin fibrosis including new worsening of skin disease, and failure to improve after worsening within 5-year window. We defined skin worsening as change in modified Rodnan skin score (mRSS) ≥5 units or ≥25%. Using strict inclusion criteria including complete mRSS, we identified 1,043 (out of 19 115) patients within the EUSTAR database for our analysis. We further restricted analysis within 887 (out of 1043) patients who had lcSSc or dcSSc at baseline. Results One-fifth of patients among the whole cohort (n = 208/1043, 19.9%) experienced mRSS worsening, including in patients with lcSSc or dcSSc at baseline (n = 193/887, 21.8%). This was largely due to new skin worsening after the 5-year window or failure to improve with worsening within the 5-year window. Patients with lower baseline mRSS and lcSSc were more likely to develop late skin fibrosis. Anti-Scl-70 was associated with progression from baseline lcSSc to dcSSc, and anticentromere was protective. Conclusions Late skin fibrosis is not uncommon in SSc. We have identified different patterns relevant to clinical practice and trial design. Late skin fibrosis is a neglected manifestation of SSc and warrants further investigation including to determine clinical outcomes and optimal therapeutic strategy.
- Published
- 2022
28. COVID‐19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies
- Author
-
Gil‐Vila, A, Naveen, R, Selva‐O'Callaghan, A, Sen, P, Nune, A, Gaur, PS, Gonzalez, RA, Lilleker, JB, Joshi, M, Agarwal, V, Kardes, S, Kim, M, Day, J, Makol, A, Milchert, M, Gheita, T, Salim, B, Velikova, T, Gracia‐Ramos, AE, Parodis, I, Nikiphorou, E, Tan, AL, Chatterjee, T, Cavagna, L, Saavedra, MA, Shinjo, SK, Ziade, N, Knitza, J, Kuwana, M, Distler, O, Chinoy, H, Aggarwal, R, Gupta, L, and COVAD Study Group
- Abstract
Introduction/Aims We studied COVID-19 vaccination-related adverse events (ADEs) 7-days post-vaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs). Methods 7-day vaccine ADEs were collected in an international patient self-reported e-survey. Descriptive statistics and multivariable regression were performed. Results 10,900 respondents [1227 IIMs; 4640 SAIDs; 5033 healthy controls (HCs), median age 42 (IQR 30-55) years, 74% female, 45% Caucasian, 69% completely vaccinated] were analysed. 76.3% IIMs patients reported minor and 4.6% major ADEs. Patients with active IIMs reported more frequent major [OR 2.7 (1.04-7.3)] and minor [OR 1.5 (1.1-2.2)] ADEs than inactive IIMs. Rashes were more frequent in IIMs [OR-2.3(1.2-4.2)] than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs [OR 1.9 (1.1-3.3), OR 2.2 (1.1-4.3)]. Overall, ADEs were less frequent in inclusion body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients Discussion 7-day post-vaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rashes in IIMs. Patients with DM, active disease may be at higher risk, and IBM patients at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID-19 through vaccination likely outweighs the risk of vaccine-related ADEs Our results may inform future guidelines regarding COVID-19 vaccination in patients with SAIDs, and specifically in IIMs. Studies to evaluate long-term outcomes and disease flares are needed to shed more light on developing future COVID-19 vaccination guidelines.
- Published
- 2022
29. Dry Eye Associated with Chronic Graft-Versus-Host Disease
- Author
-
Ogawa, Y., Kuwana, M., Yamazaki, K., Mashima, Y., Okamoto, S., Tsubota, K., Oguchi, Y., Kawakami, Y., Sullivan, David A., editor, Stern, Michael E., editor, Tsubota, Kazuo, editor, Dartt, Darlene A., editor, Sullivan, Rose M., editor, and Bromberg, B. Britt, editor
- Published
- 2002
- Full Text
- View/download PDF
30. COVAD survey 2 long-term outcomes: unmet need and protocol
- Author
-
Fazal, Z.Z., Sen, P., Joshi, M., Ravichandran, N., Lilleker, J.B., Agarwal, V., Kardes, S., Kim, M., Day, J., Makol, A., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A.E., Parodis, I., Nikiphorou, E., Tan, A.L., Chatterjee, T., Cavagna, L., Saavedra, M.A., Shinjo, S.K., Ziade, N., Selva-O’Callaghan, A., Nune, A., Knitza, J., Kuwana, M., Gutiérrez, C-E.T., Caballero-Uribe, C.V., Dey, D., Distler, O., Chinoy, H., Aggarwal, R., Gupta, L., Barman, B., Singh, Y.P., Ranjan, R., Jain, A., Pandya, S.C., Pilania, R.K., Sharma, A., Manoj, M.M., Gupta, V., Kavadichanda, C.G., Patro, Pr.S., Ajmani, S., Phatak, S., Goswami, R.P., Chowdhury, A.C., Mathew, A.J., Shenoy, P., Asranna, A., Bommakanti, K.T., Shukla, A., Pandey, A.K.R., Gaur, P.S., Mamadapur, M., Ghodke, A., Chandwar, K., Jagtap, K., Cansu, D.Ü., Yıldırım, R., Patel, A., Pauling, J.D., Wincup, C., Giannini, M., Maurier, F., Campagne, J., Meyer, A., Del Papa, N., Sambataro, G., Fabiola, A., Govoni, M., Parisi, S., Bocci, E.B., Sebastiani, G.D., Fusaro, E., Sebastiani, M., Quartuccio, L., Franceschini, F., Sainaghi, P.P., Orsolini, G., De Angelis, R., Danielli, M.G., Venerito, V., Grignaschi, S., Giollo, A., Traboco, L.S., Shaharir, S.S., Wibowo, S.A.K., Tehozol, E.A.Z., Serrano, J.R., De La Torre, I.G., Colunga‑Pedraza, I.J., Merayo-Chalico, J., Loarce-Martos, J., Prieto-González, S., Gil-Vila, A., Aranega, R., Hoff, L.S., Nakashima, R., Sato, S., Kimura, N., Kaneko, Y., Tomaras, S., Proft, F.N., Holzer, M-T, Gromova, M.A., Aharonov, O., Nagy-Vincze, M., Griger, Z., Hmamouchi, I., El bouchti, P.I., Baba, Z., Ima-Edomwonyi, U., Dedeke, I., Airenakho, E., Madu, N.H., Yerima, A., Olaosebikan, H., Chibuzo, O.C., Becky, A., Koussougbo, O.D., Palalane, E., Langguth, D., Limaye, V., Needham, M., Srivastava, N., Hudson, M., Landon-Cardinal, O., Zuleta, W.G.R., Arbeláez, Á., Cajas, J., Silva, J.A.P., Fonseca, J.E., Zimba, O., Bohdana, D., So, H., Ugarte-Gil, M.F., Chinchay, L., Bernaola, J.P., Pimentel, V., Tanveer Hasan, A.T.M., Saha, S., Vaidya, B., Fathi, H.M., Mohammed, R.H.A., Chen, Y-M, Harifi, G., El Kibbi, L., Halabi, H.M., Akawatcharangura, P., Katchamart, W., Fuentes-Silva, Y., Cabriza, K., Losanto, J., Colaman, N., Cachafeiro-Vilar, A., Bautista, G.G., Ho, E.J.G., González, R.A., Nunez, L.S., Vergara, C.M., Báez, J.T., Alonzo, H., Pastelin, C.B.S., Salinas, R.G., Obiols, A.Q., Chávez, N., Ordóñez, A.B., Argueta, S., Quijivix, D., Llerena, G.A.R., Sierra-Zorita, R., Arrieta, D., Hidalgo, E.R., Saenz, R., M., I.E., Morales, R., Calapaqui, W., Quezada, I., Arredondo, G., Fazal, Z.Z., Sen, P., Joshi, M., Ravichandran, N., Lilleker, J.B., Agarwal, V., Kardes, S., Kim, M., Day, J., Makol, A., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A.E., Parodis, I., Nikiphorou, E., Tan, A.L., Chatterjee, T., Cavagna, L., Saavedra, M.A., Shinjo, S.K., Ziade, N., Selva-O’Callaghan, A., Nune, A., Knitza, J., Kuwana, M., Gutiérrez, C-E.T., Caballero-Uribe, C.V., Dey, D., Distler, O., Chinoy, H., Aggarwal, R., Gupta, L., Barman, B., Singh, Y.P., Ranjan, R., Jain, A., Pandya, S.C., Pilania, R.K., Sharma, A., Manoj, M.M., Gupta, V., Kavadichanda, C.G., Patro, Pr.S., Ajmani, S., Phatak, S., Goswami, R.P., Chowdhury, A.C., Mathew, A.J., Shenoy, P., Asranna, A., Bommakanti, K.T., Shukla, A., Pandey, A.K.R., Gaur, P.S., Mamadapur, M., Ghodke, A., Chandwar, K., Jagtap, K., Cansu, D.Ü., Yıldırım, R., Patel, A., Pauling, J.D., Wincup, C., Giannini, M., Maurier, F., Campagne, J., Meyer, A., Del Papa, N., Sambataro, G., Fabiola, A., Govoni, M., Parisi, S., Bocci, E.B., Sebastiani, G.D., Fusaro, E., Sebastiani, M., Quartuccio, L., Franceschini, F., Sainaghi, P.P., Orsolini, G., De Angelis, R., Danielli, M.G., Venerito, V., Grignaschi, S., Giollo, A., Traboco, L.S., Shaharir, S.S., Wibowo, S.A.K., Tehozol, E.A.Z., Serrano, J.R., De La Torre, I.G., Colunga‑Pedraza, I.J., Merayo-Chalico, J., Loarce-Martos, J., Prieto-González, S., Gil-Vila, A., Aranega, R., Hoff, L.S., Nakashima, R., Sato, S., Kimura, N., Kaneko, Y., Tomaras, S., Proft, F.N., Holzer, M-T, Gromova, M.A., Aharonov, O., Nagy-Vincze, M., Griger, Z., Hmamouchi, I., El bouchti, P.I., Baba, Z., Ima-Edomwonyi, U., Dedeke, I., Airenakho, E., Madu, N.H., Yerima, A., Olaosebikan, H., Chibuzo, O.C., Becky, A., Koussougbo, O.D., Palalane, E., Langguth, D., Limaye, V., Needham, M., Srivastava, N., Hudson, M., Landon-Cardinal, O., Zuleta, W.G.R., Arbeláez, Á., Cajas, J., Silva, J.A.P., Fonseca, J.E., Zimba, O., Bohdana, D., So, H., Ugarte-Gil, M.F., Chinchay, L., Bernaola, J.P., Pimentel, V., Tanveer Hasan, A.T.M., Saha, S., Vaidya, B., Fathi, H.M., Mohammed, R.H.A., Chen, Y-M, Harifi, G., El Kibbi, L., Halabi, H.M., Akawatcharangura, P., Katchamart, W., Fuentes-Silva, Y., Cabriza, K., Losanto, J., Colaman, N., Cachafeiro-Vilar, A., Bautista, G.G., Ho, E.J.G., González, R.A., Nunez, L.S., Vergara, C.M., Báez, J.T., Alonzo, H., Pastelin, C.B.S., Salinas, R.G., Obiols, A.Q., Chávez, N., Ordóñez, A.B., Argueta, S., Quijivix, D., Llerena, G.A.R., Sierra-Zorita, R., Arrieta, D., Hidalgo, E.R., Saenz, R., M., I.E., Morales, R., Calapaqui, W., Quezada, I., and Arredondo, G.
- Abstract
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
- Published
- 2022
31. NON-SURGICAL LOCAL TREATMENTS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW
- Author
-
Campochiaro, C., Suliman, Y. A., Hughes, M., Schoones, J., Giuggioli, D., Moinzadeh, P., Maltez, N., Ross, L., Baron, M., Chung, L., Allanore, Y., Denton, C. P., Distler, O., Frech, T., Furst, D., Khanna, D., Krieg, T., Kuwana, M., Matucci-Cerinic, M., Pope, J., Alunno, A., Campochiaro, C., Suliman, Y. A., Hughes, M., Schoones, J., Giuggioli, D., Moinzadeh, P., Maltez, N., Ross, L., Baron, M., Chung, L., Allanore, Y., Denton, C. P., Distler, O., Frech, T., Furst, D., Khanna, D., Krieg, T., Kuwana, M., Matucci-Cerinic, M., Pope, J., and Alunno, A.
- Published
- 2022
32. SYSTEMIC PHARMACOLOGICAL TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW
- Author
-
Maltez, N., Ross, L., Hughes, M., Schoones, J., Baron, M., Chung, L., Campochiaro, C., Suliman, Y. A., Giuggioli, D., Moinzadeh, P., Allanore, Y., Denton, C. P., Distler, O., Frech, T., Furst, D., Khanna, D., Krieg, T., Kuwana, M., Matucci-Cerinic, M., Pope, J., Alunno, A., Maltez, N., Ross, L., Hughes, M., Schoones, J., Baron, M., Chung, L., Campochiaro, C., Suliman, Y. A., Giuggioli, D., Moinzadeh, P., Allanore, Y., Denton, C. P., Distler, O., Frech, T., Furst, D., Khanna, D., Krieg, T., Kuwana, M., Matucci-Cerinic, M., Pope, J., and Alunno, A.
- Published
- 2022
33. SURGICAL MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW.
- Author
-
Suliman, Y. A., Campochiaro, C., Hughes, M., Schoones, J., Giuggioli, D., Maltez, N., Moinzadeh, P., Ross, L., Chung, L., Allanore, Y., Baron, M., Denton, C. P., Distler, O., Frech, T., Furst, D., Khanna, D., Krieg, T., Kuwana, M., Matucci-Cerinic, M., Pope, J., Alunno, A., Suliman, Y. A., Campochiaro, C., Hughes, M., Schoones, J., Giuggioli, D., Maltez, N., Moinzadeh, P., Ross, L., Chung, L., Allanore, Y., Baron, M., Denton, C. P., Distler, O., Frech, T., Furst, D., Khanna, D., Krieg, T., Kuwana, M., Matucci-Cerinic, M., Pope, J., and Alunno, A.
- Published
- 2022
34. HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES : A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY
- Author
-
Grignaschi, S., Cavagna, L., Kim, M., R, N., Lilleker, J. B., Sen, P., Agarwal, V., Kardes, S., Day, J., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Saavedra, M. A., Shinjo, S. Katsuyuki, Ziade, N., Knitza, J., Kuwana, M., Nune, A., Distler, O., Chinoy, H., Aggarwal, R., Gupta, L., Grignaschi, S., Cavagna, L., Kim, M., R, N., Lilleker, J. B., Sen, P., Agarwal, V., Kardes, S., Day, J., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Saavedra, M. A., Shinjo, S. Katsuyuki, Ziade, N., Knitza, J., Kuwana, M., Nune, A., Distler, O., Chinoy, H., Aggarwal, R., and Gupta, L.
- Published
- 2022
- Full Text
- View/download PDF
35. TREATMENT PATTERNS OF IDIOPATHIC INFLAMMATORY MYOPATHIES : RESULTS FROM AN INTERNATIONAL COHORT OF OVER 1,400 PATIENTS
- Author
-
Aoude, M., Gupta, L., Hmamouchi, I., Grignaschi, S., Cavagna, L., Kim, M., R, N., Lilleker, J. B., Sen, P., Agarwal, V., Kardes, S., Day, J., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Saavedra, M. A., Shinjo, S. Katsuyuki, Knitza, J., Kuwana, M., Nune, A., Distler, O., Chinoy, H., Aggarwal, R., Ziade, N., Aoude, M., Gupta, L., Hmamouchi, I., Grignaschi, S., Cavagna, L., Kim, M., R, N., Lilleker, J. B., Sen, P., Agarwal, V., Kardes, S., Day, J., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Saavedra, M. A., Shinjo, S. Katsuyuki, Knitza, J., Kuwana, M., Nune, A., Distler, O., Chinoy, H., Aggarwal, R., and Ziade, N.
- Published
- 2022
- Full Text
- View/download PDF
36. COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS : RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY.
- Author
-
Gupta, L., Hoff, L. S., R, N., Sen, P., Katsuyuki Shinjo, S., Day, J., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Nune, A., Cavagna, L., Saavedra, M. A., Ziade, N., Knitza, J., Kuwana, M., Distler, O., Chinoy, H., Aggarwal, R., Gupta, L., Hoff, L. S., R, N., Sen, P., Katsuyuki Shinjo, S., Day, J., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Nune, A., Cavagna, L., Saavedra, M. A., Ziade, N., Knitza, J., Kuwana, M., Distler, O., Chinoy, H., and Aggarwal, R.
- Published
- 2022
- Full Text
- View/download PDF
37. IMPAIRED PROMIS PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS : RESULTS FROM THE MULTICENTER COVAD PATIENT REPORTED E-SURVEY
- Author
-
Yoshida, A., Kim, M., Kuwana, M., R, N., Lilleker, J. B., Sen, P., Agarwal, V., Kardes, S., Day, J., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Nune, A., Cavagna, L., Saavedra, M. A., Katsuyuki Shinjo, S., Ziade, N., Knitza, J., Distler, O., Chinoy, H., Aggarwal, R., Gupta, L., Yoshida, A., Kim, M., Kuwana, M., R, N., Lilleker, J. B., Sen, P., Agarwal, V., Kardes, S., Day, J., Makol, A., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Nune, A., Cavagna, L., Saavedra, M. A., Katsuyuki Shinjo, S., Ziade, N., Knitza, J., Distler, O., Chinoy, H., Aggarwal, R., and Gupta, L.
- Published
- 2022
- Full Text
- View/download PDF
38. COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS : RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY
- Author
-
Sen, P., R, N., Nune, A., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Day, J., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Cavagna, L., Saavedra, M. A., Shinjo, S. Katsuyuki, Ziade, N., Knitza, J., Kuwana, M., Distler, O., Chinoy, H., Aggarwal, R., Gupta, L., Sen, P., R, N., Nune, A., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Day, J., Milchert, M., Gheita, T. A., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, Ioannis, Selva-O'callaghan, A., Nikiphorou, E., Chatterjee, T., Tan, A. L., Cavagna, L., Saavedra, M. A., Shinjo, S. Katsuyuki, Ziade, N., Knitza, J., Kuwana, M., Distler, O., Chinoy, H., Aggarwal, R., and Gupta, L.
- Published
- 2022
- Full Text
- View/download PDF
39. The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19
- Author
-
Orlandi, M, Landini, N, Sambataro, G, Nardi, C, Tofani, L, Bruni, C, Bellando-Randone, S, Blagojevic, J, Melchiorre, D, Hughes, M, Denton, C, Luppi, F, Ruaro, B, Della Casa, F, Rossi, F, De Luca, G, Campochiaro, C, Spinicci, M, Zammarchi, L, Tomassetti, S, Caminati, A, Cavigli, E, Albanesi, M, Melchiorre, F, Palmucci, S, Vegni, V, Guiducci, S, Moggi-Pignone, A, Allanore, Y, Bartoloni, A, Confalonieri, M, Dagna, L, De Cobelli, F, De Paulis, A, Harari, S, Khanna, D, Kuwana, M, Taliani, G, Lavorini, F, Miele, V, Morana, G, Pesci, A, Vancheri, C, Colagrande, S, Matucci-Cerinic, M, Orlandi, Martina, Landini, Nicholas, Sambataro, Gianluca, Nardi, Cosimo, Tofani, Lorenzo, Bruni, Cosimo, Bellando-Randone, Silvia, Blagojevic, Jelena, Melchiorre, Daniela, Hughes, Michael, Denton, Christopher P, Luppi, Fabrizio, Ruaro, Barbara, Della Casa, Francesca, Rossi, Francesca W, De Luca, Giacomo, Campochiaro, Corrado, Spinicci, Michele, Zammarchi, Lorenzo, Tomassetti, Sara, Caminati, Antonella, Cavigli, Edoardo, Albanesi, Marco, Melchiorre, Fabio, Palmucci, Stefano, Vegni, Virginia, Guiducci, Serena, Moggi-Pignone, Alberto, Allanore, Yannick, Bartoloni, Alessandro, Confalonieri, Marco, Dagna, Lorenzo, De Cobelli, Francesco, De Paulis, Amato, Harari, Sergio, Khanna, Dinesh, Kuwana, Masataka, Taliani, Gloria, Lavorini, Federico, Miele, Vittorio, Morana, Giovanni, Pesci, Alberto, Vancheri, Carlo, Colagrande, Stefano, Matucci-Cerinic, Marco, Orlandi, M, Landini, N, Sambataro, G, Nardi, C, Tofani, L, Bruni, C, Bellando-Randone, S, Blagojevic, J, Melchiorre, D, Hughes, M, Denton, C, Luppi, F, Ruaro, B, Della Casa, F, Rossi, F, De Luca, G, Campochiaro, C, Spinicci, M, Zammarchi, L, Tomassetti, S, Caminati, A, Cavigli, E, Albanesi, M, Melchiorre, F, Palmucci, S, Vegni, V, Guiducci, S, Moggi-Pignone, A, Allanore, Y, Bartoloni, A, Confalonieri, M, Dagna, L, De Cobelli, F, De Paulis, A, Harari, S, Khanna, D, Kuwana, M, Taliani, G, Lavorini, F, Miele, V, Morana, G, Pesci, A, Vancheri, C, Colagrande, S, Matucci-Cerinic, M, Orlandi, Martina, Landini, Nicholas, Sambataro, Gianluca, Nardi, Cosimo, Tofani, Lorenzo, Bruni, Cosimo, Bellando-Randone, Silvia, Blagojevic, Jelena, Melchiorre, Daniela, Hughes, Michael, Denton, Christopher P, Luppi, Fabrizio, Ruaro, Barbara, Della Casa, Francesca, Rossi, Francesca W, De Luca, Giacomo, Campochiaro, Corrado, Spinicci, Michele, Zammarchi, Lorenzo, Tomassetti, Sara, Caminati, Antonella, Cavigli, Edoardo, Albanesi, Marco, Melchiorre, Fabio, Palmucci, Stefano, Vegni, Virginia, Guiducci, Serena, Moggi-Pignone, Alberto, Allanore, Yannick, Bartoloni, Alessandro, Confalonieri, Marco, Dagna, Lorenzo, De Cobelli, Francesco, De Paulis, Amato, Harari, Sergio, Khanna, Dinesh, Kuwana, Masataka, Taliani, Gloria, Lavorini, Federico, Miele, Vittorio, Morana, Giovanni, Pesci, Alberto, Vancheri, Carlo, Colagrande, Stefano, and Matucci-Cerinic, Marco
- Abstract
Objective: The aim of this study was to identify the main CT features that may help in distinguishing a progression of interstitial lung disease (ILD) secondary to SSc from COVID-19 pneumonia. Methods: This multicentric study included 22 international readers grouped into a radiologist group (RADs) and a non-radiologist group (nRADs). A total of 99 patients, 52 with COVID-19 and 47 with SSc-ILD, were included in the study. Results: Fibrosis inside focal ground-glass opacities (GGOs) in the upper lobes; fibrosis in the lower lobe GGOs; reticulations in lower lobes (especially if bilateral and symmetrical or associated with signs of fibrosis) were the CT features most frequently associated with SSc-ILD. The CT features most frequently associated with COVID- 19 pneumonia were: consolidation (CONS) in the lower lobes, CONS with peripheral (both central/peripheral or patchy distributions), anterior and posterior CONS and rounded-shaped GGOs in the lower lobes. After multivariate analysis, the presence of CONs in the lower lobes (P < 0.0001) and signs of fibrosis in GGOs in the lower lobes (P < 0.0001) remained independently associated with COVID-19 pneumonia and SSc-ILD, respectively. A predictive score was created that was positively associated with COVID-19 diagnosis (96.1% sensitivity and 83.3% specificity). Conclusion: CT diagnosis differentiating between COVID-19 pneumonia and SSc-ILD is possible through a combination of the proposed score and radiologic expertise. The presence of consolidation in the lower lobes may suggest COVID-19 pneumonia, while the presence of fibrosis inside GGOs may indicate SSc-ILD.
- Published
- 2022
40. Antimelanoma differentiation‐associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis
- Author
-
Matsushita, T., Mizumaki, K., Kano, M., Yagi, N., Tennichi, M., Takeuchi, A., Okamoto, Y., Hamaguchi, Y., Murakami, A., Hasegawa, M., Kuwana, M., Fujimoto, M., and Takehara, K.
- Published
- 2017
- Full Text
- View/download PDF
41. AB0584 MANAGEMENT OF REFERRALS, TREATMENT STRATEGY, AND RESEARCH CHALLENGES IN POLYMYALGIA RHEUMATICA AMONGST RHEUMATOLOGISTS WORLDWIDE: A QUESTIONNAIRE BASED STUDY
- Author
-
Overgaard Donskov, A., primary, Mackie, S., additional, Hauge, E. M., additional, Toro Gutiérrez, C., additional, Hansen, I., additional, Hemmig, A., additional, Van der Maas, A., additional, Gheita, T. A., additional, Dalsgaard Nielsen, B., additional, Douglas, K., additional, Conway, R., additional, Rezus, E., additional, Dasgupta, B., additional, Monti, S., additional, Matteson, E., additional, Sattui, S. E., additional, Matza, M., additional, Ocampo, V., additional, Bran, A., additional, Appenzeller, S., additional, Goecke, A., additional, Colman MC Leod, N., additional, Keen, H., additional, Kuwana, M., additional, Gupta, L., additional, Salim, B., additional, Harifi, G., additional, Erraoui, M., additional, Ziade, N., additional, Al-Ani, N. A., additional, Ajibade, A., additional, Knitza, J., additional, Frølund, L., additional, Yates, M., additional, Pimentel-Quiroz, V., additional, Lyrio, A., additional, Sandovici, M., additional, Van der Geest, K., additional, Helliwell, T., additional, Brouwer, E., additional, Dejaco, C., additional, and Keller, K., additional
- Published
- 2022
- Full Text
- View/download PDF
42. OP0062 EFFICACY AND SAFETY OF ADALIMUMAB WITH LOW AND HIGH DOSE-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: THE RANDOMISED CONTROLLED MIRACLE STUDY
- Author
-
Tamai, H., primary, Ikeda, K., additional, Miyamoto, T., additional, Taguchi, H., additional, Kuo, C. F., additional, Shin, K., additional, Hirata, S., additional, Okano, Y., additional, Sato, S., additional, Yasuoka, H., additional, Choi, I. A., additional, Park, S. H., additional, Weng, M. Y., additional, Kuwana, M., additional, Lee, Y. J., additional, Ishii, T., additional, Kim, J., additional, Kameda, H., additional, Kojima, T., additional, Baek, H. J., additional, Hsu, P. N., additional, Huang, C. M., additional, Cheng, T. T., additional, Sung, W. Y., additional, Taninaga, T., additional, Mori, M., additional, Miyagishi, H., additional, Sato, Y., additional, Takeuchi, T., additional, and Kaneko, Y., additional
- Published
- 2022
- Full Text
- View/download PDF
43. OP0112 THE EVER-LARGEST ASIAN GWAS FOR SYSTEMIC SCLEROSIS AND TRANS-POPULATION META-ANALYSIS IDENTIFIED SEVEN NOVEL LOCI AND A CANDIDATE CAUSAL SNP IN A CIS-REGULATORY ELEMENT OF THE FCGR REGION
- Author
-
Ishikawa, Y., primary, Tanaka, N., additional, Asano, Y., additional, Kodera, M., additional, Shirai, Y., additional, Akahoshi, M., additional, Hasegawa, M., additional, Matsushita, T., additional, Kazuyoshi, S., additional, Motegi, S., additional, Yoshifuji, H., additional, Yoshizaki, A., additional, Kohmoto, T., additional, Takagi, K., additional, Oka, A., additional, Kanda, M., additional, Tanaka, Y., additional, Ito, Y., additional, Nakano, K., additional, Kasamatsu, H., additional, Utsunomiya, A., additional, Sekiguchi, A., additional, Niro, H., additional, Jinnin, M., additional, Makino, K., additional, Makino, T., additional, Ihn, H., additional, Yamamoto, M., additional, Suzuki, C., additional, Takahashi, H., additional, Nishida, E., additional, Morita, A., additional, Yamamoto, T., additional, Fujimoto, M., additional, Kondo, Y., additional, Goto, D., additional, Sumida, T., additional, Ayuzawa, N., additional, Yanagida, H., additional, Horita, T., additional, Atsumi, T., additional, Endo, H., additional, Shima, Y., additional, Kumanogoh, A., additional, Hirata, J., additional, Otomo, N., additional, Suetsugu, H., additional, Koike, Y., additional, Tomizuka, K., additional, Yoshino, S., additional, Liu, X., additional, Ito, S., additional, Hikino, K., additional, Suzuki, A., additional, Momozawa, Y., additional, Ikegawa, S., additional, Ishikawa, O., additional, Takehara, K., additional, Torii, T., additional, Sato, S., additional, Okada, Y., additional, Mimori, T., additional, Matsuda, F., additional, Matsuda, K., additional, Imoto, I., additional, Matsuo, K., additional, Kuwana, M., additional, Kawaguchi, Y., additional, Ohmura, K., additional, and Terao, C., additional
- Published
- 2022
- Full Text
- View/download PDF
44. OP0161 TREATMENT PATTERNS OF IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM AN INTERNATIONAL COHORT OF OVER 1,400 PATIENTS
- Author
-
Aoude, M., primary, Gupta, L., additional, Hmamouchi, I., additional, Grignaschi, S., additional, Cavagna, L., additional, Kim, M., additional, R, N., additional, Lilleker, J. B., additional, Sen, P., additional, Agarwal, V., additional, Kardes, S., additional, Day, J., additional, Makol, A., additional, Milchert, M., additional, Gheita, T. A., additional, Salim, B., additional, Velikova, T., additional, Gracia-Ramos, A. E., additional, Parodis, I., additional, Selva-O’callaghan, A., additional, Nikiphorou, E., additional, Chatterjee, T., additional, Tan, A. L., additional, Saavedra, M. A., additional, Katsuyuki Shinjo, S., additional, Knitza, J., additional, Kuwana, M., additional, Nune, A., additional, Distler, O., additional, Chinoy, H., additional, Aggarwal, R., additional, and Ziade, N., additional
- Published
- 2022
- Full Text
- View/download PDF
45. POS0899 HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY.
- Author
-
Grignaschi, S., primary, Cavagna, L., additional, Kim, M., additional, R, N., additional, Lilleker, J. B., additional, Sen, P., additional, Agarwal, V., additional, Kardes, S., additional, Day, J., additional, Makol, A., additional, Milchert, M., additional, Gheita, T. A., additional, Salim, B., additional, Velikova, T., additional, Gracia-Ramos, A. E., additional, Parodis, I., additional, Selva-O’callaghan, A., additional, Nikiphorou, E., additional, Chatterjee, T., additional, Tan, A. L., additional, Saavedra, M. A., additional, Katsuyuki Shinjo, S., additional, Ziade, N., additional, Knitza, J., additional, Kuwana, M., additional, Nune, A., additional, Distler, O., additional, Chinoy, H., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2022
- Full Text
- View/download PDF
46. POS0900 SYSTEMIC PHARMACOLOGICAL TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW
- Author
-
Maltez, N., primary, Ross, L., additional, Hughes, M., additional, Schoones, J., additional, Baron, M., additional, Chung, L., additional, Campochiaro, C., additional, Suliman, Y. A., additional, Giuggioli, D., additional, Moinzadeh, P., additional, Allanore, Y., additional, Denton, C. P., additional, Distler, O., additional, Frech, T., additional, Furst, D., additional, Khanna, D., additional, Krieg, T., additional, Kuwana, M., additional, Matucci-Cerinic, M., additional, Pope, J., additional, and Alunno, A., additional
- Published
- 2022
- Full Text
- View/download PDF
47. POS0201 COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY.
- Author
-
Gupta, L., primary, Hoff, L. S., additional, R, N., additional, Sen, P., additional, Katsuyuki Shinjo, S., additional, Day, J., additional, Lilleker, J. B., additional, Agarwal, V., additional, Kardes, S., additional, Kim, M., additional, Makol, A., additional, Milchert, M., additional, Gheita, T. A., additional, Salim, B., additional, Velikova, T., additional, Gracia-Ramos, A. E., additional, Parodis, I., additional, Selva-O’callaghan, A., additional, Nikiphorou, E., additional, Chatterjee, T., additional, Tan, A. L., additional, Nune, A., additional, Cavagna, L., additional, Saavedra, M. A., additional, Ziade, N., additional, Knitza, J., additional, Kuwana, M., additional, Distler, O., additional, Chinoy, H., additional, and Aggarwal, R., additional
- Published
- 2022
- Full Text
- View/download PDF
48. POS0066 THE PHENOTYPE OF MIXED CONNECTIVE TISSUE DISEASE PATIENTS HAVING ASSOCIATED INTERSTITIAL LUNG DISEASE
- Author
-
Boleto, G., primary, Reiseter, S., additional, Hoffmann-Vold, A. M., additional, Mirouse, A., additional, Cacoub, P., additional, Matucci-Cerinic, M., additional, Silvério-António, M., additional, Fonseca, J. E., additional, Riccieri, V., additional, Le Tallec, E., additional, Lescoat, A., additional, Tandaipan, J. L., additional, Castellví, I., additional, Airò, P., additional, Kuwana, M., additional, Kavosi, H., additional, Avouac, J., additional, and Allanore, Y., additional
- Published
- 2022
- Full Text
- View/download PDF
49. POS0855 IMPAIRED PROMIS PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS: RESULTS FROM THE MULTICENTER COVAD PATIENT REPORTED E-SURVEY
- Author
-
Yoshida, A., primary, Kim, M., additional, Kuwana, M., additional, R, N., additional, Lilleker, J. B., additional, Sen, P., additional, Agarwal, V., additional, Kardes, S., additional, Day, J., additional, Makol, A., additional, Milchert, M., additional, Gheita, T. A., additional, Salim, B., additional, Velikova, T., additional, Gracia-Ramos, A. E., additional, Parodis, I., additional, Selva-O’callaghan, A., additional, Nikiphorou, E., additional, Chatterjee, T., additional, Tan, A. L., additional, Nune, A., additional, Cavagna, L., additional, Saavedra, M. A., additional, Katsuyuki Shinjo, S., additional, Ziade, N., additional, Knitza, J., additional, Distler, O., additional, Chinoy, H., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2022
- Full Text
- View/download PDF
50. OP0157 EFFECT OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) AND RISK FACTORS FOR RAPID DECLINE IN FORCED VITAL CAPACITY: FURTHER ANALYSES OF THE SENSCIS TRIAL
- Author
-
Khanna, D., primary, Maher, T., additional, Volkmann, E., additional, Allanore, Y., additional, Smith, V., additional, Assassi, S., additional, Kreuter, M., additional, Hoffmann-Vold, A. M., additional, Kuwana, M., additional, Stock, C., additional, Alves, M., additional, Sambevski, S., additional, and Denton, C. P., additional
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.